BNTX Key Statistics, Chart & Performance
The current stock price of BNTX is 99.58 USD. In the past month the price decreased by -8.97%. In the past year, price decreased by -18.46%.
BNTX Latest News, Press Relases and Analysis
BNTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.57 | 410.25B | ||
| AMGN | AMGEN INC | 15.57 | 183.32B | ||
| GILD | GILEAD SCIENCES INC | 15.47 | 157.21B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.7 | 109.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.52 | 83.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 842.86 | 56.35B | ||
| INSM | INSMED INC | N/A | 44.08B | ||
| NTRA | NATERA INC | N/A | 32.70B | ||
| BIIB | BIOGEN INC | 10.89 | 26.72B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.38 | 21.94B | ||
| INCY | INCYTE CORP | 16.44 | 20.61B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.13B |
Related stock screener links
About BNTX
Company Profile
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,772 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Company Info
BIONTECH SE-ADR
An der Goldgrube 12
Mainz RHEINLAND-PFALZ 55131 DE
CEO: Ugur Sahin
Employees: 6772
Phone: 4949613190840
BIONTECH SE-ADR / BNTX FAQ
Can you describe the business of BIONTECH SE-ADR?
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,772 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Can you provide the latest stock price for BIONTECH SE-ADR?
The current stock price of BNTX is 99.58 USD. The price increased by 3.15% in the last trading session.
Does BIONTECH SE-ADR pay dividends?
BNTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of BNTX stock?
BNTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in BIONTECH SE-ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BNTX.
What is the expected growth for BNTX stock?
The Revenue of BIONTECH SE-ADR (BNTX) is expected to decline by -16.11% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of BNTX stock?
BIONTECH SE-ADR (BNTX) has a market capitalization of 23.94B USD. This makes BNTX a Large Cap stock.
BNTX Technical Analysis
BNTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BNTX. Both the profitability and the financial health of BNTX get a neutral evaluation. Nothing too spectacular is happening here.
BNTX Financial Highlights
Over the last trailing twelve months BNTX reported a non-GAAP Earnings per Share(EPS) of -2.74. The EPS decreased by -20.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.68% | ||
| ROE | -3.09% | ||
| Debt/Equity | 0.01 |
BNTX Forecast & Estimates
29 analysts have analysed BNTX and the average price target is 138.91 USD. This implies a price increase of 39.5% is expected in the next year compared to the current price of 99.58.
For the next year, analysts expect an EPS growth of -72.94% and a revenue growth -16.11% for BNTX